{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:33:26Z","timestamp":1771054406109,"version":"3.50.1"},"reference-count":7,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>High-dose cytarabine is associated with gastrointestinal and cerebellar toxicity, precluding its use for older or unfit patients with acute myeloid leukemia (AML). Aspacytarabine, an inactive prodrug of cytarabine, was evaluated as monotherapy in a phase 2b study of patients unfit for intensive chemotherapy (NCT03435848). Sixty-five patients with AML were treated with aspacytarabine 4.5 g\/m2 per day (equimolar to 3 g\/m2 per day cytarabine) for 6 doses per treatment. The median age was 75 years; 60.6% of patients had de novo AML, 28.8% had AML secondary to myelodysplastic syndrome, and 10.6% had therapy-related AML. Overall, 36.9% achieved complete remission (CR) with full count recovery. CR rates in patients with secondary AML, patients with prior treatment with hypomethylating agents, and patients with TP53 mutation were 26.7%, 25%, and 36%, respectively. Median overall survival was 9\u00a0months (range, 6-15.9) and was not reached among responders. Hematologic recovery was observed in all responding patients by day 26 without prolonged cytopenias. Adverse events typically precluding the use of high-dose cytarabine in older or unfit patients were not observed. These data suggest that aspacytarabine may be an effective regimen with a reduction in the attendant toxicities associated with high-dose cytarabine, an important consideration when treating AML and other hematologic disorders that use high-dose cytarabine. This trial was registered at www.clinicaltrials.gov as #NCT03435848.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010943","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:12:08Z","timestamp":1698696728000},"page":"7494-7500","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-1896","authenticated-orcid":false,"given":"Jessica K.","family":"Altman","sequence":"first","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Koprivnikar","sequence":"additional","affiliation":[{"name":"4John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[{"name":"4John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[{"name":"5Georgia Cancer Center, Augusta University, Augusta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Keng","sequence":"additional","affiliation":[{"name":"6University of Virginia Cancer Center-Charlottesville, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Frankfurt","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Abaza","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale L.","family":"Bixby","sequence":"additional","affiliation":[{"name":"7University of Michigan Comprehensive Cancer Center, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-3210","authenticated-orcid":false,"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[{"name":"8University of Maryland School of Medicine, College Park, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Burch","sequence":"additional","affiliation":[{"name":"9Baylor Scott & White Research Institute, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-0712","authenticated-orcid":false,"given":"Bhavana","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"10Arthur G James Cancer Hospital Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[{"name":"11Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Elizabeth","family":"Percival","sequence":"additional","affiliation":[{"name":"12University of Washington and Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofir","family":"Wolach","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Rabin Medical Center, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[{"name":"14Internal Medicine, Hematology-Oncology, West Virginia University, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-4807","authenticated-orcid":false,"given":"Chezi","family":"Ganzel","sequence":"additional","affiliation":[{"name":"15Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail","family":"Roboz","sequence":"additional","affiliation":[{"name":"16Department of Hematology\/Oncology, Weill Cornell Medical College, New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itai","family":"Levi","sequence":"additional","affiliation":[{"name":"17Soroka University Medical Center, Beersheba, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Gourevitch","sequence":"additional","affiliation":[{"name":"17Soroka University Medical Center, Beersheba, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Flaishon","sequence":"additional","affiliation":[{"name":"18Biosight Ltd, Tel-Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshi","family":"Tessler","sequence":"additional","affiliation":[{"name":"18Biosight Ltd, Tel-Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Blumberg","sequence":"additional","affiliation":[{"name":"18Biosight Ltd, Tel-Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela","family":"Gengrinovitch","sequence":"additional","affiliation":[{"name":"18Biosight Ltd, Tel-Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ben Yakar","sequence":"additional","affiliation":[{"name":"18Biosight Ltd, Tel-Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"3Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel"},{"name":"15Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"22","key":"2023122214570851000_bib1","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2023122214570851000_bib2","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/bloodadvances.2019000468","article-title":"BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1\/2a study","volume":"3","author":"Zuckerman","year":"2019","journal-title":"Blood Adv"},{"issue":"24","key":"2023122214570851000_bib3","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023122214570851000_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023122214570851000_bib5","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"14","key":"2023122214570851000_bib6","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"2023122214570851000_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/24\/7494\/2177875\/blooda_adv-2023-010943-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/24\/7494\/2177875\/blooda_adv-2023-010943-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:57:21Z","timestamp":1703257041000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/24\/7494\/498526\/Aspacytarabine-for-the-treatment-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":7,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010943","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}